Target- |
MechanismFGFR2 antagonists |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
3HP-2827在FGFR2异常的手术不可切除/转移性实体瘤患者中的安全性、耐受性、药代动力学和疗效的开放、多中心1/2期临床研究
[Translation] An open-label, multicenter phase 1/2 clinical study of the safety, tolerability, pharmacokinetics and efficacy of 3HP-2827 in patients with surgically unresectable/metastatic solid tumors with FGFR2 aberrations
评估3HP-2827在FGFR2异常的手术不可切除/转移性实体瘤患者中的安全性、耐受性和疗效
[Translation] To evaluate the safety, tolerability and efficacy of 3HP-2827 in patients with surgically unresectable/metastatic solid tumors with FGFR2 aberrations
An Open-Label, Multi-center Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Activity of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3HP-2827 in the treatment of unresectable or metastatic solid tumors with FGFR2 alterations.
A First-in-human, Open-label, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Activity of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3HP-2827 in the treatment of unresectable or metastatic solid tumors with FGFR2 alterations. Patients will be enrolled in two stages: dose escalation stage (Stage I) and expansion stage (Stage II).
100 Clinical Results associated with Sikang Ruiqi (Suzhou) Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Sikang Ruiqi (Suzhou) Pharmaceutical Co., Ltd.
100 Deals associated with Sikang Ruiqi (Suzhou) Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Sikang Ruiqi (Suzhou) Pharmaceutical Co., Ltd.